Eli Lilly and Company reported promising topline findings from its SURPASS-PEDS Phase 3 trial for Mounjaro (tirzepatide), which is a major advancement for the treatment of pediatric diabetes. Significant improvements in blood sugar control and weight management were shown in the trial, which assessed the GIP/GLP-1 dual receptor agonist in children and adolescents with type 2 diabetes.
At 30 weeks, Mounjaro demonstrated a statistically significant decrease in A1C levels, the main indicator of blood sugar control, as compared to a placebo, and the trial achieved all of its major secondary goals. Participants who received Mounjaro treatment saw an average 2.2% decrease in their A1C. The study also demonstrated the effect of Mounjaro on weight, showing that an average BMI decrease of 11.2% was achieved at a dose of 10 mg. Throughout the study’s 52-week extension, these beneficial benefits on A1C and BMI persisted.
Read More: Eli Lilly’s Oral Weight-Loss Drug Orforglipron Shows Promising Results in Phase 3 Trial
It was discovered that Mounjaro’s safety and tolerability profile in this juvenile population was largely in line with what was shown in adult research. The most frequent adverse effects, which mostly happened during the dose escalation period, were gastrointestinal in nature and were usually mild to moderate in intensity.
A first-in-class treatment, Mounjaro is a once-weekly injectable prescription medication that stimulates the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Significant weight loss in adults has been seen as a result of this dual mode of action, which also helps to lower blood sugar levels. Mounjaro may prove to be a significant new therapy option for younger individuals battling type 2 diabetes, according to the encouraging outcomes of the SURPASS-PEDS trial.
This most recent announcement comes after tirzepatide saw a number of encouraging outcomes. Under the names Mounjaro for adults with type 2 diabetes and Zepbound for individuals who are obese or overweight and have weight-related health issues, the medication is already approved. Adults with type 2 diabetes and existing cardiovascular disease have also shown cardiovascular advantages from it.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
The positive results in the pediatric group provide Mounjaro a new opportunity and raise hopes for improved treatment of type 2 diabetes in kids and teens, a condition that is becoming a bigger global health issue. It is anticipated that the complete findings of the SURPASS-PEDS study will be presented at future medical conferences and submitted for publication in peer-reviewed journals.
Last Modified:
Graduated from the University of Kerala'20 with B.Sc. Botany & Biotechnology. Post-graduation in Biotechnology from the University of Kerala'22. Internship experience in Cancer Research.
